Los puntos clave no están disponibles para este artículo en este momento.
AZD5991, a human MCL-1 inhibitor, was assessed for safety, tolerability, pharmacokinetics, and antitumor activity as monotherapy and in combination with venetoclax in patients with relapsed or refractory hematologic malignancies.
Desai et al. (Wed,) studied this question.